MITSUBISHI PHARMA IN-LICENSES CNS COMPOUND TO BRAINCELLS

San Diego-based drug discovery and development company BrainCells Inc. has in-licensed a clinical-stage compound from Mitsubishi Pharma Corp. (MPC) that BCI will reposition and develop for the treatment of central nervous system (CNS) diseases, including mood disorders. BioSpectrum (http://www.biospectrumasia.com/content/110806JPN1333.asp)